Versus Lenalidomide News Today

SEATTLE, Dec. 05, 2023 -- Adaptive Biotechnologies Corporation , a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to...

Daratumumab combination is recommended for use within the NHS in England and Wales for treating adults with newly diagnosed multiple myeloma where a stem cell transplant is unsuitableEligible patients throughout England and Wales can now access alternative combination treatment option which has been shown to delay d...

/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new analyses from the Phase 3 MAIA study of DARZALEX® (daratumumab)...

05.12.2022 - SEATTLE, Dec. 05, 2022 (GLOBE NEWSWIRE) - Adaptive Biotechnologies Corporation (Nasdaq: ADPT), together with its collaborators, will present data from more than 30 abstracts showcasing the benefit of Adaptive’s next-generation sequencing ...

Investigational daratumumab quadruple combination regimen shows responses in newly diagnosed, transplant-eligible patients with multiple myeloma in randomised Phase 2 GRIFFIN study1 Real-world...

Investigational daratumumab quadruple combination regimen shows responses in newly diagnosed, transplant-eligible patients with multiple myeloma in randomised Phase 2 GRIFFIN study1 Real-world evidence